(S)-(-)-2-amino-7-ethoxycarbonylmethoxytetralin | 153388-58-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(-)-2-amino-7-ethoxycarbonylmethoxytetralin
• 英文别名: (S)-2-amino-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene；ethyl (S)-(2-amino-1,2,3,4-tetrahydronaphthalen-7-yl-oxy)acetate；(S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydro-2-naphthalenamine；ethyl 2-[[(7S)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate
• CAS: 153388-58-0
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: NZCUEXDFXFPWRJ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-3-氯苯基环氧乙烷 、 (S)-(-)-2-amino-7-ethoxycarbonylmethoxytetralin 以 二甲基亚砜 为溶剂， 生成 N-<(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl>-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine
  参考文献：
  名称：

  Synthesis and β-adrenergic activity of atypical β-adrenergic phenylethanolaminotetralin stereoisomers

  摘要：

  A series of substituted phenylethanolaminotetralins were synthesized as pure stereoisomers and their ability to stimulate atypical beta-adrenoceptors selectively was evaluated. The compounds in vitro relative potencies were assessed using the atypical beta response of inhibition of rat proximal colon motility and the typical beta 1 (increase in guinea-pig right atrial frequency) and beta 2 (guinea-pig tracheal relaxation and rat uterus motility inhibition) responses. Compound 42 (SR 58611A) was found to be the most potent and selective.

  DOI：

  10.1016/0223-5234(94)90095-7
• 作为产物：
  描述：

  (S)-2-氨基-7-羟基四氢化萘 在 TEA 、 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 4.0h， 生成 (S)-(-)-2-amino-7-ethoxycarbonylmethoxytetralin
  参考文献：
  名称：

  Synthesis and β-adrenergic activity of atypical β-adrenergic phenylethanolaminotetralin stereoisomers

  摘要：

  A series of substituted phenylethanolaminotetralins were synthesized as pure stereoisomers and their ability to stimulate atypical beta-adrenoceptors selectively was evaluated. The compounds in vitro relative potencies were assessed using the atypical beta response of inhibition of rat proximal colon motility and the typical beta 1 (increase in guinea-pig right atrial frequency) and beta 2 (guinea-pig tracheal relaxation and rat uterus motility inhibition) responses. Compound 42 (SR 58611A) was found to be the most potent and selective.

  DOI：

  10.1016/0223-5234(94)90095-7

文献信息

• Propanolaminotetralines, preparation thereof and compositions containing same
  申请人：——

  公开号：US20040034070A1

  公开（公告）日：2004-02-19

  The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.

  该发明涉及苯氧丙醇胺，含有它们的药物组合物，制备它们的方法，以及在治疗通过β-3激动剂作用改善的疾病中使用它们的方法。
• Alternative synthesis of the chiral atypical β-adrenergicphenylethanolaminotetraline agonist SR58611A using enantioselective hydrogenation
  作者：Marc Devocelle、André Mortreux、Francine Agbossou、Jean-Robert Dormoy

  DOI：10.1016/s0040-4039(99)00807-2

  日期：1999.6

  We have developed an alternative synthesis of the atypical β-adrenergic phenylethanolaminotetraline agonist SR58611A. Two key intermediates have been synthesised involving enantioselective hydrogenation of an aminoketone and an enamide providing the corresponding amino alcohol and amide in >96 and >98 % ee respectively.

  我们已经开发出非典型的β-肾上腺素苯基乙醇氨基四氢呋喃激动剂SR58611A的另一种合成方法。已合成了两种关键中间体，涉及对氨基酮和烯酰胺的对映选择性氢化，分别提供了> 96％ee和> 98％ee的相应氨基醇和酰胺。
• Propanolamine derivatives
  申请人：——

  公开号：US20020006956A1

  公开（公告）日：2002-01-17

  This invention relates to new propanolamine derivatives presented by the following formula [I]: 1 wherein R 1 is hydrogen or lower alkenyloxy, R 2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy, R 3 is hydrogen or N-protective group, n is an integer of 1 or 2, and salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, to processes for the preparation thereof and to a pharmaceutical composition comprising the same.

  本发明涉及一种新的丙醇胺衍生物，其化学式如下：1其中R1为氢或较低的烯丙氧基，R2为羧基(较低)烷氧基或保护羧基(较低)烷氧基，R3为氢或N-保护基，n为1或2的整数，以及其盐。这些衍生物具有肠道选择性交感神经兴奋剂、抗溃疡、抗胰腺炎、脂肪分解和抗多尿活性，本发明还涉及其制备方法和包含该衍生物的制药组合物。
• Phenylethanolaminotetralincarboxamide derivatives
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US06046192A1

  公开（公告）日：2000-04-04

  The present invention relates to a phenylethanolaminotetralincarboxamide derivative represented by the general formula: ##STR1## (wherein A represents a lower alkylene group; B represents an amino group, a di(lower alkyl)amino group or a 3 to 7-membered alicyclic amino group which may contain an oxygen atom in the ring; the carbon atom marked with * represents a carbon atom in (R) configuration, (S) configuration or a mixture thereof; and the carbon atom marked with (S) represents a carbon atom in (S) configuration) and a pharmaceutically acceptable salt thereof, which have a selective .beta..sub.2 -adrenergic receptor stimulating effect with relieved burdens on the heart such as tachycardia and are useful as an agent for the prevention of threatened abortion and premature labor, a bronchodilator, and an agent for pain remission and promoting stone removal in urolithiasis.

  本发明涉及一种由通式所表示的苯乙醇胺四环酰胺衍生物：##STR1##（其中A代表较低的烷基链；B代表氨基、二（较低的烷基）氨基或3至7成员的脂环氨基，该环中可能含有一个氧原子；标有*的碳原子代表（R）构型、（S）构型或它们的混合物中的一个碳原子；标有（S）的碳原子代表（S）构型的碳原子），以及其药学上可接受的盐，具有选择性β2肾上腺素能受体刺激作用，并减轻对心脏的负担，如心动过速，可用作预防威胁性流产和早产、支气管扩张剂、疼痛缓解剂和促进尿路结石排出剂。
• Ethers de la 2-amino-7-hydroxytétraline
  申请人：ELF SANOFI

  公开号：EP0347313A2

  公开（公告）日：1989-12-20

  Ethers de la 2-amino-7-hydroxytétraline de formule dans laquelle R′ représente un méthyle substitué par un groupe carboxy ou carbalcoxy inférieur; un procédé pour leur préparation à partir de la 2-amino-7-hydroxytétraline, N-protection, O-alkylation et N-déprotection; intermédiaires N-protégés; et utilisation des composés I pour la préparation des phényléthanolaminotétralines cor­respondantes.

  2-氨基-7-羟基四氢萘的醚类，其式为 其中 R′代表被羧基或低级烷氧基取代的甲基；由 2-氨基-7-羟基四氢萘，N-保护，O-烷基化和 N-脱保护制备它们的工艺；N-保护的中间体；以及使用化合物 I 制备相应的苯乙醇胺四氢萘。